<DOC>
	<DOCNO>NCT01247675</DOCNO>
	<brief_summary>This study investigate safety , tolerability , pharmacokinetic profile ( PK ) , pharmacodynamic response ( PD ) three different dose ACP-001 give once-a-week compare one dose-level approve daily human growth hormone product period 4 week ( 4 weekly administration versus 28 daily administration ) adult Growth Hormone Deficiency .</brief_summary>
	<brief_title>A Safety , Pharmacokinetic Pharmacodynamic Study ACP-001 ( TransCon hGH ) Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female 20 70 year Body Mass Index ( BMI , kg/m2 ) 19.0 36.0 kg/m2 , inclusive Adult Growth Hormone Deficient ( AHGD ) patient document growth hormone deficiency define Consensus guideline diagnosis treatment adult GH deficiency II ( Consensus Guidelines 1998 2007 ) Fertile females must agree use appropriate contraceptive method negative pregnancy test inclusion GH replacement therapy least 3 month Willing maintain current activity level trial Subjects able willing provide write informed consent authorization protect health information disclosure accordance Good Clinical Practice ( GCP ) History hypersensitivity and/or idiosyncrasy test compound excipients employ study . Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method . Reliable method woman orally administer hormonal contraceptive , surgical intervention ( e.g . tubal ligation ) , intrauterine device ( IUD ) sexual abstinence . Active malignant disease malignant disease within last 5 year Proliferative retinopathy judge retinaphoto within last year Heart insufficiency judge investigator and/or NYHA 3 great ( NYHA criterion diagnosis diseases heart , 1994 ) Subjects uncontrolled diabetes HbA1c 8.0 % and/or insulin treatment Stable pituitary hormone replacement therapy le 3 month Impaired liver function judge investigator hepatic transaminase &gt; 2 time upper limit normal Impaired kidney function judge investigator and/or creatinine clearance &lt; 50 mL/min and/or serum creatinine &gt; 1.4 mg/dL Participation another interventional clinical study involve investigational compound within 3 month prior enrolment study participation another interventional clinical study involve investigational compound study . Subjects unable comply requirement study opinion investigator participate study . History presence alcohol abuse drug abuse . Patients known history , presence , antihGH / antiPEG antibody</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>